Hemostasis in Intracranial Hemorrhage.

Area of Science:

• Neurology
• Hematology
• Emergency Medicine

Background:

• Spontaneous non-traumatic intracerebral hemorrhage (ICH) leads to high morbidity and mortality globally.
• Hematoma expansion, often occurring within 4 hours of symptom onset, significantly worsens patient outcomes.
• Effective ultra-early hemostatic therapy is crucial for limiting hematoma expansion in ICH.

Purpose of the Study:

• To review and recommend ultra-early hemostatic interventions for intracerebral hemorrhage (ICH).
• To address treatment strategies based on antithrombotic use and underlying coagulopathies.
• To guide management for patients with ICH associated with various anticoagulants and antiplatelet agents.

Main Methods:

• Review of current literature and treatment guidelines for intracerebral hemorrhage (ICH).
• Analysis of evidence for interventions in patients with ICH related to antiplatelet agents, vitamin K antagonists, and novel oral anticoagulants.
• Evaluation of specific reversal agents and blood products for different anticoagulant classes.

Main Results:

• Discontinuation of antiplatelet agents and platelet transfusion recommended for antiplatelet-associated ICH undergoing surgery.
• 3-factor or 4-factor prothrombin complex concentrates (PCCs) are strongly recommended for vitamin K antagonist-associated ICH (INR >1.4).
• Activated charcoal recommended for novel oral anticoagulant-associated ICH within 2 hours; specific PCCs or idarucizumab for direct thrombin inhibitors; 4-factor PCC or activated PCC preferred for Factor Xa inhibitors.

Conclusions:

• Tailored ultra-early hemostatic interventions are essential for managing intracerebral hemorrhage (ICH) based on causative agent.
• Appropriate use of reversal agents and blood products can limit hematoma expansion and improve clinical outcomes.
• Further research into optimal hemostatic strategies for ICH is warranted.